Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program
ConclusionREMS program implementation and enforcement were not associated with significant changes in ESA initiation, adding to concerns over the degree to which certain REMS programs enhance patient safety.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Aranesp | Cancer | Cancer & Oncology | Drugs & Pharmacology | Epogen | Insurance | Insurers | Procrit | Study | Warnings